Can Gilead (GILD) Stock Continue Rising in 2027?

insidermonkey.com · 2026-10-12

Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cancer drugs.

TickrTrends take: Gilead Sciences operates in the Healthcare sector and is currently assessed as overvalued according to TickrTrends valuation metrics. Given this overvaluation designation, investors focused on valuation should monitor whether the company can deliver earnings growth substantial enough to justify its current stock price levels heading into 2027. The gap between current valuation and intrinsic value becomes particularly important to track if the stock continues its upward momentum, as it could either narrow through improved fundamentals or widen if valuations expand further without corresponding business performance.

Read the full story at insidermonkey.com →